ANTX Company Profile and Key Details

ANTX has shown mixed momentum, gaining 3.51% over the past week and -0.84% over the past quarter, though year-to-date performance is up 3.51%. Short-term trend indicators are bullishly aligned (SMA20 -1.3%, SMA50 -6.15%, SMA200 -7.56%). The stock’s 14-day RSI is 45.06 (neutral), while the ATR of 0.06 points to moderate volatility. The stock remains hovering near 52-week lows, trading -31.61% below its high and over 6.0% above its low. Average 10-day trading volume of 16.19 million shares is significantly above the 3-month average of 1.22 million, indicating heightened recent market interest.

AN2 Therapeutics, Inc. has 27.40 million shares outstanding. The public float is 16.15 million shares, elevated short interest at 0.33% of float. This equals 53.14 thousand shares. The short ratio is 0.78 days. Institutional investors hold 52.75% of the float. Insiders own 25.39%. Shah Rajeev M. holds 3.77 million shares, Leonard Braden Michael has 3.22 million shares and Adjuvant Global Health Technology Fund DE, L.P. has 2.21 million shares. Over the past six months, insider transactions show net selling. They sold 53.28 thousand shares across 11 transactions.

AN2 Therapeutics, Inc. generated EPS of -$1.13 over the past year. Five-year average earnings growth is -41.25%. Wall Street analysts project EPS growth of 22.52% annually over the next five years. The latest quarter delivered EPS of -$0.31. The next quarter is forecast at -$0.24. Next year's EPS is expected at $1.25. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $5.00 to $5.00. The high target offers -4.76% upside. The low target suggests -4.76% downside. The mean target is $5.00. This offers -4.76% upside. AN2 Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 34.31%. The prior quarter beat by -32.26%. Over the last six quarters, Apple has recorded several small beats. These include -23.81% in August 13, 2024.

AN2 Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.72. This means the shares are trading above this model’s fair value.

AN2 Therapeutics, Inc. (NASDAQ:ANTX) closed at $5.25 USD, gaining $2.40 (84.21%) from the previous close of $2.85. The stock is currently mid-range between its 52-week high and low $1.00 and $6.91. With a market capitalization of about $143.86 million, AN2 Therapeutics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.03). Key stats such as the average daily volume over the past year has been around 1.22 million shares, trading with heavier-than-usual volume. Headquartered in Menlo Park, CA, AN2 Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Eric E. Easom, the company employs approximately 22 people and listed since March 25, 2022. AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases.

AN2 Therapeutics, Inc. (NASDAQ:ANTX) shares are flat 3.51% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows AN2 Therapeutics, Inc. trading at a premium to the broader market with a P/E of -4.72. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $14.25, suggesting 171.43% upside. Our AI forecast model points to short-term weakness (-20.76% over two weeks), a medium-term fall (-33.52% over three months), and a longer-term gain (0.95% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that AN2 Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -20.76%, with price expected at $4.16 by March 23, 2026, within a range of $3.81 to $4.47 3-Month Outlook: Projected fall of -33.52%, reaching $3.49 by June 05, 2026, with a range of $2.98 to $3.71. 1-Year Outlook: Projected gain of 0.95%, with price at $5.30 by March 09, 2027, within a range of $0.00 to $0.00.

AN2 Therapeutics, Inc. trades at a P/E ratio of -4.72, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.66 suggesting the stock is closer to book value. The P/FCF stands at -4.86, also below market averages.